Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Paolo Strati; Mohamed Amin Ahmed; Nathan H. Fowler; Loretta J. Nastoupil; Felipe Samaniego; Luis E. Fayad; Fredrick B. Hagemeister; Jorge E. Romaguera; Alma Rodriguez; Michael Wang; Jason R. Westin; Chan Cheah; Mansoor Noorani; Lei Feng; Richard E. Davis; Sattva S. Neelapu

doi:10.3324/haematol.2019.230649

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Paolo Strati, Mohamed Amin Ahmed, Nathan H. Fowler, Loretta J. Nastoupil, Felipe Samaniego, Luis E. Fayad, Fredrick B. Hagemeister, Jorge E. Romaguera, Alma Rodriguez, Michael Wang, Jason R. Westin, Chan Cheah, Mansoor Noorani, Lei Feng, Richard E. Davis, Sattva S. Neelapu

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

_T ^he (SUV _{ic frontline}^impact_max) on the ^of_regimens^{pre-treatment} outcome _has of _not follicular ^maximum_{been explored.} lymphoma ^standardized_We (FL) _performed following ^uptake_a specif- _retro-^value spective analysis of 346 patients with advanced stage follicular lymphoma (FL) without histological evidence of transformation, and analyzed the impact of SUV_max on outcome after frontline therapy. Fifty-two (15%) patients had a SUV_max >18, and a large lymph node ≥6 cm was the only factor associating with SUV_max >18 on multivariate analysis (odds ratio 2.7, 95% confidence interval [CI]: 1.3-5.3, P=0.006). The complete response rate was significantly lower among patients treated with non-anthracycline-based regimens if SUV_max was >18 (45% vs. 92%, P<0.001), but not among patients treated with R-CHOP (P=1). SUV_max >18 was associated with significantly shorter progression-free survival among patients treated with non-anthracycline-based regimens (77 months vs. not reached, P=0.02), but not among patients treated with R-CHOP (P=0.73). SUV_max >18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (8-year OS 70% vs. 90%, P=0.02) and non-anthracycline-based frontline regimens (8-year OS 50% vs. 85%, P=0.001). In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment.

Original language	English (US)
Pages (from-to)	1907-1913
Number of pages	7
Journal	Haematologica
Volume	105
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2019.230649
State	Published - Jul 1 2020

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.3324/haematol.2019.230649

Cite this

Strati, P., Ahmed, M. A., Fowler, N. H., Nastoupil, L. J., Samaniego, F., Fayad, L. E., Hagemeister, F. B., Romaguera, J. E., Rodriguez, A., Wang, M., Westin, J. R., Cheah, C., Noorani, M., Feng, L., Davis, R. E., & Neelapu, S. S. (2020). Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica, 105(7), 1907-1913. https://doi.org/10.3324/haematol.2019.230649

Strati, P, Ahmed, MA, Fowler, NH, Nastoupil, LJ , Samaniego, F , Fayad, LE, Hagemeister, FB, Romaguera, JE, Rodriguez, A, Wang, M , Westin, JR, Cheah, C, Noorani, M, Feng, L , Davis, RE & Neelapu, SS 2020, 'Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma', Haematologica, vol. 105, no. 7, pp. 1907-1913. https://doi.org/10.3324/haematol.2019.230649

@article{b0cb62b4c6b442a19cb3378f03a147c0,

title = "Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma",

abstract = "T he (SUV ic frontlineimpactmax) on the ofregimenspre-treatment outcome has of not follicular maximumbeen explored. lymphoma standardizedWe (FL) performed following uptakea specif- retro-value spective analysis of 346 patients with advanced stage follicular lymphoma (FL) without histological evidence of transformation, and analyzed the impact of SUVmax on outcome after frontline therapy. Fifty-two (15%) patients had a SUVmax >18, and a large lymph node ≥6 cm was the only factor associating with SUVmax >18 on multivariate analysis (odds ratio 2.7, 95% confidence interval [CI]: 1.3-5.3, P=0.006). The complete response rate was significantly lower among patients treated with non-anthracycline-based regimens if SUVmax was >18 (45% vs. 92%, P<0.001), but not among patients treated with R-CHOP (P=1). SUVmax >18 was associated with significantly shorter progression-free survival among patients treated with non-anthracycline-based regimens (77 months vs. not reached, P=0.02), but not among patients treated with R-CHOP (P=0.73). SUVmax >18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (8-year OS 70% vs. 90%, P=0.02) and non-anthracycline-based frontline regimens (8-year OS 50% vs. 85%, P=0.001). In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment.",

author = "Paolo Strati and Ahmed, {Mohamed Amin} and Fowler, {Nathan H.} and Nastoupil, {Loretta J.} and Felipe Samaniego and Fayad, {Luis E.} and Hagemeister, {Fredrick B.} and Romaguera, {Jorge E.} and Alma Rodriguez and Michael Wang and Westin, {Jason R.} and Chan Cheah and Mansoor Noorani and Lei Feng and Davis, {Richard E.} and Neelapu, {Sattva S.}",

note = "Publisher Copyright: {\textcopyright}2020 Ferrata Storti Foundation",

year = "2020",

month = jul,

day = "1",

doi = "10.3324/haematol.2019.230649",

language = "English (US)",

volume = "105",

pages = "1907--1913",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

TY - JOUR

T1 - Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

AU - Strati, Paolo

AU - Ahmed, Mohamed Amin

AU - Fowler, Nathan H.

AU - Nastoupil, Loretta J.

AU - Samaniego, Felipe

AU - Fayad, Luis E.

AU - Hagemeister, Fredrick B.

AU - Romaguera, Jorge E.

AU - Rodriguez, Alma

AU - Wang, Michael

AU - Westin, Jason R.

AU - Cheah, Chan

AU - Noorani, Mansoor

AU - Feng, Lei

AU - Davis, Richard E.

AU - Neelapu, Sattva S.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - T he (SUV ic frontlineimpactmax) on the ofregimenspre-treatment outcome has of not follicular maximumbeen explored. lymphoma standardizedWe (FL) performed following uptakea specif- retro-value spective analysis of 346 patients with advanced stage follicular lymphoma (FL) without histological evidence of transformation, and analyzed the impact of SUVmax on outcome after frontline therapy. Fifty-two (15%) patients had a SUVmax >18, and a large lymph node ≥6 cm was the only factor associating with SUVmax >18 on multivariate analysis (odds ratio 2.7, 95% confidence interval [CI]: 1.3-5.3, P=0.006). The complete response rate was significantly lower among patients treated with non-anthracycline-based regimens if SUVmax was >18 (45% vs. 92%, P<0.001), but not among patients treated with R-CHOP (P=1). SUVmax >18 was associated with significantly shorter progression-free survival among patients treated with non-anthracycline-based regimens (77 months vs. not reached, P=0.02), but not among patients treated with R-CHOP (P=0.73). SUVmax >18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (8-year OS 70% vs. 90%, P=0.02) and non-anthracycline-based frontline regimens (8-year OS 50% vs. 85%, P=0.001). In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment.

AB - T he (SUV ic frontlineimpactmax) on the ofregimenspre-treatment outcome has of not follicular maximumbeen explored. lymphoma standardizedWe (FL) performed following uptakea specif- retro-value spective analysis of 346 patients with advanced stage follicular lymphoma (FL) without histological evidence of transformation, and analyzed the impact of SUVmax on outcome after frontline therapy. Fifty-two (15%) patients had a SUVmax >18, and a large lymph node ≥6 cm was the only factor associating with SUVmax >18 on multivariate analysis (odds ratio 2.7, 95% confidence interval [CI]: 1.3-5.3, P=0.006). The complete response rate was significantly lower among patients treated with non-anthracycline-based regimens if SUVmax was >18 (45% vs. 92%, P<0.001), but not among patients treated with R-CHOP (P=1). SUVmax >18 was associated with significantly shorter progression-free survival among patients treated with non-anthracycline-based regimens (77 months vs. not reached, P=0.02), but not among patients treated with R-CHOP (P=0.73). SUVmax >18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (8-year OS 70% vs. 90%, P=0.02) and non-anthracycline-based frontline regimens (8-year OS 50% vs. 85%, P=0.001). In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment.

UR - http://www.scopus.com/inward/record.url?scp=85087469552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087469552&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.230649

DO - 10.3324/haematol.2019.230649

M3 - Article

C2 - 31601688

AN - SCOPUS:85087469552

SN - 0390-6078

VL - 105

SP - 1907

EP - 1913

JO - Haematologica

JF - Haematologica

IS - 7

ER -

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this